Colorectal Cancer Drugs Market Outlook Till 2031 | Innovation, Drug Approvals and Japan's Role in R&D

The Global Colorectal Cancer Drugs Market reached US$ 13.6 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 18.1 billion by 2030. The Global Colorectal Cancer Drugs Market is expected to exhibit a CAGR of 3.7% during the forecast period 2024-2031.

Latest Updates:

Takeda's FRUZAQLA (fruquintinib) approved by MHLW

In September 2024, Japan's Ministry of Health, Labour and Welfare greenlit fruquintinib (marketed as FRUZAQLA), marking the first targeted therapy in over a decade for unresectable advanced or recurrent colorectal cancer after chemotherapy

Global FRESCO-2 trial confirms efficacy in Japan

The approval was based on robust FRESCO-2 Phase III data showing significant improvements in both overall survival and progression-free survival among Japanese and international patients

Ono/BMS submit Opdivo + Yervoy combo in MSI‐High CRC

In late 2024, Ono Pharmaceutical and Bristol-Myers Squibb filed for a supplemental Japanese approval for Opdivo plus Yervoy to treat MSI-High unresectable or recurrent colorectal cancer based on positive CheckMate‐8HW outcomes

Henlius initiates phase III mCRC trial in JapanThe international ASTRUM‐015 trial, testing serplulimab with bevacizumab and chemo in first-line metastatic colorectal cancer, has begun dosing patients in Japan as of late 2024

Unlock exclusive insights with our detailed sample report (Corporate Email ID gets priority access): https://datamintelligence.com/download-sample/colorectal-cancer-drugs-market?kb

Colorectal Cancer Drugs Market Overview

Colorectal cancer drugs are medications used to treat cancers of the colon. These drugs include chemotherapy, targeted therapies, and immunotherapy that aim to shrink tumors, prevent recurrence, and improve survival rates. They may be used alone or in combination based on the cancer stage and patient condition.

Research Methodology:

The global Colorectal Cancer Drugs Market research report is based on a combination of primary and secondary data sources. The study carefully analyzes various factors influencing the industry, including government regulations, market dynamics, competitive landscape, historical trends, current conditions, and technological progress. It also evaluates future developments, related industry trends, market volatility, growth prospects, potential obstacles, and emerging challenges.

Segment Covered in the Colorectal Cancer Drugs Market:

By Type: Vascular endothelial growth factor inhibitors, Programmed Cell Death Protein 1/PD1 Ligand 1 (PD1/PDL1) Inhibitors, Tyrosine Kinase (TKI) Inhibitors, Immunomodulators, and BRAF or MEK Inhibitors

By Therapy: Immunotherapy, Targeted Therapy, and Chemotherapy

By Distribution channels: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others

Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/colorectal-cancer-drugs-market?kb

List of the Key Players in the Colorectal Cancer Drugs Market:

Genentech, Inc., Eli Lilly, and Company, Pfizer, Sanofi S.A., Bristol-Myers Squibb, Amgen, Merck & Co., Inc., Teva Pharmaceuticals, Novartis, GlaxoSmithKline, among others.

Industry Development:

In May 2023, Innovent Biologics announced that its drug candidate IBI351 was granted Breakthrough Therapy Designation in China for the treatment of advanced colorectal cancer patients carrying the KRASG12C mutation. The company is widely recognized for its focus on developing high-quality therapies for critical diseases, including cancer, metabolic disorders, autoimmune conditions, and ophthalmologic diseases.

In April 2023, HUTCHMED Limited submitted a New Drug Application (NDA) to the U.S. FDA for fruquintinib (HMPL-013), aimed at treating patients with refractory metastatic colorectal cancer (mCRC).

On January 19, 2023, Seagen Inc. revealed that the U.S. FDA granted accelerated approval for TUKYSA (tucatinib) in combination with trastuzumab. This approval targets adult patients with HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer, particularly those who have progressed after receiving fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.

Regional Analysis for Colorectal Cancer Drugs Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

The Report Includes:

➡ A descriptive analysis of demand-supply gap, market size estimation, SWOT analysis, PESTEL Analysis and forecast in the global market.

➡ Top-down and bottom-up approach for regional analysis

➡ Go-to-market Strategy.

➡ Neutral perspective on the market performance.

➡ Customized regional/country reports as per request and country level analysis.

➡ Potential & niche segments and regions exhibiting promising growth covered.

People Also Ask:

➠ What are the global sales, production, consumption, imports, and exports in the Colorectal Cancer Drugs market?

➠ Who are the top manufacturers, and what are their capacity, production, sales, pricing, and revenue stats?

➠ What key opportunities and challenges do vendors face in the Colorectal Cancer Drugs industry?

➠ Which product types, applications, or end-users are driving market growth, and what is their market share?

➠ What are the major growth drivers and restraints of the Colorectal Cancer Drugs market?

Stay informed with the latest industry insights-start your subscription now: https://www.datamintelligence.com/reports-subscription?kb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.